Cardiopulmonary resuscitation (CPR) after cardiac arrest (CA) is often a cause of secondary neurological impairment, which results in considerable morbidity and mortality. Suppression of protein degradation of key blood-brain barrier (BBB) components after CPR could maintain the stability of the BBB function, and as such minimize secondary neurological damage and improve long-term prognosis after ischemia reperfusion injury.

Additional early-stage research and drug discovery news in brief, from: Coya Therapeutics, Inmed Pharmaceuticals, Model Medicines, RS Biotherapeutics.

Regor Pharmaceuticals Inc. has divulged phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi, skeletal abnormalities and scoliosis, among others.

CVI Pharmaceuticals Ltd. has identified thyroid hormone receptor (THR)-β agonists reported to be useful for the treatment of atherosclerosis, hypercholesterolemia, hyperlipidemia, hepatic steatosis, thyroid cancer, obesity and hypothyroidism.

Kangbaida (Sichuan) Biotechnology Co. Ltd. has described DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Hangzhou Polymed Biopharmaceuticals Inc. has synthesized crystalline forms of compounds acting as FLT3 (FLK2/STK1) and interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, cardiovascular, neurological and inflammatory disorders.

Antibody Therapeutics Inc. has disclosed integrin receptor antagonists reported to be useful for the treatment of pulmonary fibrosis, renal fibrosis and hepatic fibrosis.

Researchers from Shenyang Pharmaceutical University and affiliated organizations have detailed the discovery and preclinical characterization of novel reversible lysine-specific demethylase 1 (LSD1) inhibitors as candidates for acute myeloid leukemia (AML) therapy.